Cognition Therapeutics, Inc. The company's focus is on creating candidates that target the σ-2 receptor complex, which plays a crucial role in regulating cellular damage and stress responses within the central nervous system. Their lead candidate, CT1812, is an innovative small molecule drug that is designed to selectively bind to the σ-2 receptor complex.

By doing so, it aims to restore the damaged cellular processes that drive diseases like Alzheimer's disease, dry age-related macular degeneration (dry AMD), geographic atrophy, and other related conditions. Cognition Therapeutics is committed to advancing the treatment options for these debilitating disorders. To learn more about their ongoing and planned clinical studies, you can visit their pipeline.

With a strong foundation in science and a dedicated team, Cognition Therapeutics is at the forefront of developing novel therapies that have the potential to make a significant impact on patients' lives